SBB Research Group’s Edwards Lifesciences EW Stock Holding History

SBB Research Group’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,577	Closed	-$213K	–	60
2022 Q3	$213K	Buy	+2,577	New	+$248K	0.3%	42

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

SBB Research Group's EW Position: Q4 2022 in Review

SBB Research Group sold out of Edwards Lifesciences (EW) in Q4 2022, closing a stake of 2,577 shares — an estimated $213K sold.

SBB Research Group first reported a position in EW in Q3 2022 and held it in 1 quarter. The position peaked at $213K in Q3 2022. 1,228 funds tracked by Wall St. Rank hold EW as of Q4 2022.

SBB Research Group reported no remaining Edwards Lifesciences position as of Q4 2022 after selling out during the quarter.
SBB Research Group sold 2,577 Edwards Lifesciences shares in Q4 2022, an estimated $213K.
SBB Research Group first reported a position in Edwards Lifesciences in Q3 2022 and held it in 1 quarter.
SBB Research Group's Edwards Lifesciences position peaked at $213K in Q3 2022.
1,228 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2022.

Based on SBB Research Group's 13F filing for Q4 2022, filed 9 Feb 2023.